Further strengthening of the Board
We are very pleased to announce that Mr. Peter Bonne Eriksen has been elected to the Cytovac Board. Peter Bonne Eriksen will bring new very important skills to the board of directors and the company. Peter Bonne can contribute with extensive experience in clinical drug development and the regulatory approval process for new medical drugs. This is a subject area in which Peter Bonne Eriksen has worked for many years at management level at NOVO Nordisk. This expansion of CytoVacs Board is a further strengthening of the Board’s expertise in a specialized area, that the company is moving into, and we look forward to working with Peter.